About Bioversys
Bioversys is a company based in Basel (Switzerland) founded in 2008 by Marc Gitzinger. Bioversys has raised $62.46 million across 10 funding rounds from investors including Gates Foundation, European Investment Bank and CARB-X. Bioversys offers products and services including BV100, Alpibectir, BV200, and BV500. Bioversys operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Basel, Switzerland
- Founders Marc Gitzinger
- Stage Public
- SectorsHealthcare
- Website bioversys.com
- Social LinkedIn X
- Legal Name Bioversys Ag
- Total Equity Funding$62.46M (USD)
in 10 rounds
- Latest Funding Round$9.03M (USD), Series C
Jan 2023
- InvestorsGates Foundation
& 10 more
Products & Services of Bioversys
Bioversys offers a comprehensive portfolio of products and services, including BV100, Alpibectir, BV200, and BV500.
Targets serious hospital infections like A. baumannii.
Addresses MDR-TB and tuberculosis meningitis.
Focuses on Staphylococcus aureus infections.
Treats nontuberculous mycobacterial infections.
Funding Insights of Bioversys
Bioversys has successfully raised a total of $62.46M across 10 strategic funding rounds. The most recent funding activity was a Series C round of $9.03 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $62.46M
- Total Rounds 10
- Last Round Series C — $9.03M
- First Round $2.3M
(May 2009)
- Investors Count 11
All 10 funding rounds of Bioversys with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2023 | $9.03M | Series C | – | AMR Action Fund | – |
| Jun 2022 | $25.07M | Series C | – | AMR Action Fund | |
| Jun 2021 | $4.35M | Grant | – | – | |
| Apr 2021 | $23.83M | Debt – Venture | – | – | |
| Sep 2020 | $21.03M | Series B | – | – | |
| Oct 2019 | $3.94M | Grant | – | – | |
| Jun 2019 | $7.76M | Grant | – | – | |
| Nov 2017 | $5.04M | Series A | – | – | – |
| Jan 2017 | $279,175 | Grant | – | – | |
| May 2009 | $2.3M | Seed | – | – |
11 investors in total: 11 institutional.
Investors in Bioversys
Bioversys has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Gates Foundation, European Investment Bank and CARB-X.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in antimicrobial resistance treatment development. | – | amractionfund.com | - | |
CR Ventures is recognized as a global life-science investor. | – | cr-ventures.com | Boston, United States | |
University backed startup accelerator | – | venturekick.ch | Schlieren, Switzerland | |
Business Angels Switzerland is focused on investing in innovative startups. | – | businessangels.ch | Worb, Switzerland | |
Finance and advisory services for infrastructure projects are provided. | 1958 | eib.org | Luxembourg, Luxembourg | |
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed. | 2016 | carb-x.org | Boston, United States | |
Wellcome is a global charitable foundation focused on health research. | – | wellcome.ac.uk | London, United Kingdom | |
Education and research policies are overseen by the ministry. | 1955 | bmbf.de | Berlin, Germany | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Health research and innovation are funded through public-private partnerships. | 2021 | imi.europa.eu | Brussels, Belgium |
Investor details for Bioversys
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Bioversys
23 people are tracked at Bioversys (10 in leadership, 4 in board & advisors, 9 in team).
| Name | Role | Group |
|---|---|---|
Marc Gitzinger | Founder & CEO | Leadership |
Philipp Schmid | Head Of Finance | Leadership |
Sylvia Mundt | Executive Assistant to CEO | Leadership |
Vincent Trebosc | Laboratory Head | Leadership |
Glenn Dale | Chief Development Officer | Leadership |
Alessia Michelotti | Head Of Chemistry | Leadership |
Daniel Ritz | Chief Scientific Officer | Leadership |
Jürgen Jäger | Head, Chemistry, Manufacturing & Controls | Leadership |
Hernán Levett | Chief Financial Officer | Leadership |
Jonathan James Butcher | Head, Business Development & Alliance Management | Leadership |
Seng Chin Mah | Chairman | Board & advisors |
William Jenkins | Board Member | Board & advisors |
David Hunstad | Board Member | Board & advisors |
Marina von Schönau | Board Member | Board & advisors |
Peter Jager | Senior Advisor, Strategy & Market Access | Team |
Françoise Jung | Senior Research & Alliance Manager | Team |
Birgit Schellhorn | Senior Research Associate | Team |
Line Hofmann | Research Scientist | Team |
Pierre Delique | Clinical Project Manager | Team |
Mélanie Appertet | Research Associate Microbiology | Team |
3 more people are available in the full profile.
Complete people profiles for Bioversys
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Bioversys
Bioversys is a publicly listed company on the SIX with ticker symbol BIOV in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Feb 2025
- Listed onSWX: BIOV
- Listed entityBioVersys AG
- Exchange sectorHealth technology
- ISINCH0210362643
- Share price26.50 CHF · 2026-10-09
- Market capitalisation155,428,521.00 CHF
- EPS (diluted, trailing year)-4.51 CHF
- Volume (last session)301
Timeline of Bioversys
4 dated milestones of Bioversys across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Bioversys is founded.
- Funding First funding round of $2.3M.
- Funding Latest funding round, Series C, of $9.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Bioversys
Bioversys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| nabriva.com | 2006 | Vienna, Austria | $193.08M | – | Pleuromutilin antibiotics are developed for MDR infections. | |
| melinta.com | 2000 | Morristown, United States | $186M | 290 | Developer of bacterial ribosome-targeting drugs for MDR infections | |
| iterumtx.com | 2015 | Dublin, Ireland | $78.1M | – | Developer of antibiotics for MDR infections | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. | |
| paratekpharma.com | 1996 | Boston, United States | $96.48M | 205 | Therapeutics for antimicrobial resistant infections are developed. | |
| locus-bio.com | 2015 | Raleigh, United States | $67.33M | 74 | Developer of therapeutics for infectious disease and inflammatory indications | |
| vedantabio.com | 2010 | Cambridge, United States | $350.49M | 71 | Therapeutics for infectious and autoimmune diseases are developed. | |
| allecra.com | 2013 | – | $44.44M | – | Antibiotics for multi-drug-resistant bacterial infections are developed. | |
| cubist.com | 1993 | Lexington, United States | – | 895 | Pharmaceuticals for acute care bacterial infections are developed and commercialized. |
Detailed competitors of Bioversys
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bioversys
The website of Bioversys (bioversys.com) receives about 10.1K visits a month.
- Monthly visits10.1K
▲ 9.5% vs previous month
Latest news on Bioversys
Complete news archive for Bioversys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Bioversys
10 companies that operate in the same segment as Bioversys (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Bioversys
Bioversys was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Bioversys is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Marc Gitzinger is the current CEO of Bioversys. They have also founded this company.
Bioversys is a funded company, having raised a total of $62.46M across 10 funding rounds to date. The company's 1st funding round was a Seed of $2.3M, raised on May 2009.
Bioversys was founded in 2008 and is based in Basel, Switzerland. Therapeutics targeting antimicrobial resistance are developed and commercialized by the company within the biotechnology sector. Focus is placed on treatments for life-threatening infections caused by multi-drug resistant bacteria. The pipeline features BV100, aimed at Acinetobacter baumannii infections, and Alpibectir, intended for tuberculosis management. Operations emphasize innovation in antibacterial products to address global health challenges.
Bioversys's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Bioversys offers BV100, Alpibectir, BV200, and BV500.
Yes, Bioversys is publicly traded on SIX under the ticker symbol BIOV.
Bioversys has 11 investors. Key investors include Gates Foundation, European Investment Bank, CARB-X, European Union, and BMBF.
Bioversys operates through Bioversys Ag.